In another phase 1 trial, the oncolytic measles virus encoding thyroidal sodium iodide symporter (NIS) (MV-NIS) was delivered once i.t. to evaluate safety and tolerability in patients with metastatic BC (NCT01846091). This evidence concerns the gene SLC5A5 and breast cancer.